News
IPHA
1.480
+5.71%
0.080
Weekly Report: what happened at IPHA last week (0420-0424)?
Weekly Report · 2d ago
Innate Pharma to attend D. Boral Capital Global Conference in investor meetings
PUBT · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Innate Pharma (IPHA), Emergent Biosolutions (EBS)
TipRanks · 04/20 10:40
Weekly Report: what happened at IPHA last week (0413-0417)?
Weekly Report · 04/20 09:10
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Benzinga · 04/17 19:01
Innate Pharma to present MATISSE Phase 2 interim IPH5201 results at AACR 2026
PUBT · 04/17 19:00
Novo Nordisk cuts Innate Pharma stake below 5% voting rights threshold
PUBT · 04/13 17:14
Innate Pharma publishes 2025 annual report
PUBT · 04/13 13:44
Weekly Report: what happened at IPHA last week (0406-0410)?
Weekly Report · 04/13 09:10
Innate Pharma reports 93,860,680 shares outstanding, 94,465,868 exercisable voting rights
PUBT · 04/13 05:00
Innate Pharma announces shareholder annual general meeting
PUBT · 04/13 05:00
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
Barchart · 04/13 00:00
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Barchart · 04/13 00:00
Innate Pharma says Novo Nordisk stake falls to 4.9% of shares, 4.9% voting rights
Reuters · 04/09 14:55
Innate Pharma to present at AACR oncology partnering event
Reuters · 04/08 05:00
Innate Pharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 04/07 17:56
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
Benzinga · 04/07 17:45
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
TipRanks · 04/07 16:55
Weekly Report: what happened at IPHA last week (0330-0403)?
Weekly Report · 04/06 09:10
Innate Pharma participates in Kempen Life Sciences Conference investor meetings
Reuters · 04/03 05:00
More
Webull provides a variety of real-time IPHA stock news. You can receive the latest news about Innate Pharma Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.